Can a rheumatoid arthritis patient in remission who is taking methotrexate stop etanercept (Enbrel) and continue methotrexate alone?

Can a Rheumatoid Arthritis Patient on Methotrexate Stop Etanercept?

No, a rheumatoid arthritis patient in remission on methotrexate plus etanercept should not stop etanercept abruptly, but if they have been in sustained remission for at least 6 months, gradual discontinuation of etanercept is preferred over stopping methotrexate.

Guideline-Based Approach to Medication Withdrawal

The 2021 ACR guidelines provide clear direction: gradual discontinuation of methotrexate is conditionally recommended over gradual discontinuation of the biologic (etanercept) for patients taking methotrexate plus a biologic who wish to discontinue a DMARD 1. This means if you must taper one medication, keep the etanercept and taper the methotrexate instead.

However, the 2020 EULAR recommendations state that if a patient is in persistent remission after having tapered glucocorticoids, one can consider tapering biologics or tsDMARDs, especially if this treatment is combined with a csDMARD 2. The key word here is "persistent remission" - meaning sustained low disease activity or remission for at least 6 months before considering any tapering 1.

Evidence from Clinical Trials

The highest quality recent evidence comes from the 2021 SEAM-RA trial, which directly addresses your question 3. In this study of 253 RA patients in sustained remission on methotrexate plus etanercept:

• 49.5% maintained remission on etanercept monotherapy (after stopping methotrexate)
• Only 28.7% maintained remission on methotrexate monotherapy (after stopping etanercept)
• 52.9% maintained remission on continued combination therapy

The difference was statistically significant (p=0.004), demonstrating that etanercept monotherapy is superior to methotrexate monotherapy in maintaining remission 3. Time to disease worsening was significantly shorter in patients who stopped etanercept compared to those who stopped methotrexate (p<0.001) 3.

Practical Algorithm for Decision-Making

Step 1: Verify Remission Status

• Confirm SDAI ≤3.3 or DAS28 <2.6
• Ensure remission has been sustained for at least 6 months
• Patient must have no active complaints or signs of disease activity

Step 2: Choose Tapering Strategy (if reduction is necessary)

Preferred order based on evidence:

1. Continue both medications at current dose (lowest flare risk) 1
2. If tapering is necessary, taper methotrexate first, keep etanercept 1, 3
3. If you must taper etanercept, reduce dose gradually (50mg weekly → 25mg weekly) rather than stopping 4, 5
4. Never stop both medications simultaneously 1

Step 3: Monitor Closely

• Assess disease activity every 3 months during tapering
• Patient-reported outcomes (pain, global assessment) may worsen before objective disease activity measures 6
• If disease worsens, restart combination therapy immediately - 70-80% will recapture remission 3

Critical Caveats and Pitfalls

Common mistake: Stopping etanercept because "the patient feels fine." The SEAM-RA trial showed that 71.3% of patients who stopped etanercept experienced disease worsening within 48 weeks, compared to only 50.5% who stopped methotrexate 3.

Safety consideration: The FDA label for Enbrel (etanercept) warns about serious infections and malignancies, but these risks must be balanced against the moderate-to-high risk for flare and potential for irreversible long-term damage associated with stopping DMARDs 1, 7.

Cost-effectiveness: While reducing medication burden is appealing, the 2023 study showed that maintaining saturated doses of etanercept is more cost-effective than under-dosing, with an incremental cost-effectiveness ratio of $5,791/QALY 8.

When Etanercept Discontinuation May Be Considered

The 2022 EULAR update acknowledges that with sustained remission, DMARDs may be tapered but should not be stopped 9. If financial constraints or patient preference necessitate stopping one medication:

• Etanercept can be gradually discontinued if remission has been sustained for ≥6 months 2
• Continue methotrexate at therapeutic dose 1
• Use gradual discontinuation (reduce to 25mg weekly for 3-6 months before stopping) rather than abrupt cessation 1, 4
• Maintain close monitoring with rescue therapy plan in place 3

The evidence strongly favors keeping etanercept and tapering methotrexate if only one medication can be continued, as etanercept monotherapy maintains remission better than methotrexate monotherapy 3.